An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness

Drug and Alcohol Dependence

Volumn 153, Issue , 2015, Pages 293-299

  Murphy, Sean M ^a   McDonell, Michael G ^b   McPherson, Sterling ^a   Srebnik, Debra ^c   Angelo, Frank ^b   Roll, John M ^a   Ries, Richard K ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Child and Adolescent Services   (United States)

Author keywords

Contingency management; Cost effectiveness; Serious mental illness; Stimulant use

Indexed keywords

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY MENTAL HEALTH; CONTINGENCY MANAGEMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE ABUSE; TREATMENT PLANNING; BEHAVIOR THERAPY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; MENTAL DISORDERS; MENTAL HEALTH SERVICE; SUBSTANCE-RELATED DISORDERS; WASHINGTON;

CENTRAL STIMULANT AGENT;

ADULT; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMMUNITY MENTAL HEALTH SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MENTAL DISORDERS; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE-RELATED DISORDERS; WASHINGTON;

EID: 84937642470     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.05.004     Document Type: Article

References (62)

1. Abram K.M., Teplin L.A. Co-occurring disorders among mentally ill jail detainees Implications for public policy. Am. Psychol. 1991, 46:1036-1045.
2. Baker A., Bucci S., Lewin T.J., Kay-Lambkin F., Constable P.M., Carr V.J. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br. J. Psychiatry 2006, 188:439-448.
3. Barrowclough C., Haddock G., Wykes T., Beardmore R., Conrod P., Craig T., Davies L., Dunn G., Eisner E., Lewis S., Moring J., Steel C., Tarrier N. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010, 341:c6325.
4. Bartels S.J., Drake T.G.B., Clark R.E., Bush R.E.P.W., Noordsy D.L. Substance abuse in schizophrenia: service utilization and costs. J. Nerv. Ment. Dis. 1993, 181:227-232.
5. Bellack A.S., Bennett M.E., Gearon J.S., Brown C.H., Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch. Gen. Psychiatry 2006, 63:426-432.
6. Benishek L.A., Dugosh K.L., Kirby K.C., Matejkowski J., Clements N.T., Seymour B.L., Festinger D.S. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction 2014, 109:1426-1436.
7. Bennett M.E., Bellack A.S., Gearon J.S. Treating substance abuse in schizophrenia. An initial report. J. Subst. Abuse Treat. 2001, 20:163-175.
8. Bureau of Labor Statistics Occupational Outlook Handbook 2014, Bureau of Labor Statistics, 〈http://www.bls.gov/ooh/home.htm〉.
9. Daneluzzo E., Arduini L., Rinaldi O., Di Domenico M., Petruzzi C., Kalyvoka A., Rossi A. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr Res. 2002, 56:129-136.
10. de Leon J., Gurpegui M., Diaz F.J. Epidemiology of comorbid tobacco use and schizophrenia: thinking about risks and protective factors. J. Dual Diagn. 2007, 3:9-25.
11. Drake R.E., McHugo G.J., Clark R.E., Teague G.B., Xie H., Miles K., Ackerson T.H. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am. J. Orthopsychiatry 1998, 68:201.
12. Drake R.E., O'Neal E.L., Wallach M.A. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J. Subst. Abuse Treat. 2008, 34:123-138.
13. Dutra L., Stathopoulou G., Basden S., Leyro T., Powers M., Otto M. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 2008, 165:179-187.
14. Eisenberg D.P., Aniskin D.B., White L., Stein J.A., Harvey P.D., Galynker I.I. Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: a confirmatory factor analysis of the positive and negative syndrome scale. Psychopathology 2009, 42:242.
15. Epstein J.F., Hourani L.L., Heller D.C. Predictors of treatment receipt among adults with a drug use disorder. Am. J. Drug Alcohol Abuse 2004, 30:841-869.
16. Galanter M., Dermatis H., Egelko S., De Leon G. Homelessness and mental illness in a professional- and peer-led cocaine treatment clinic. Psychiatr. Serv. 1998, 49:533-535.
17. Glick H., Doshi J.A., Sonnad S.S., Polsky D. Economic Evaluation in Clinical Trials 2007, Oxford University Press.
18. Haywood T.W., Kravitz H.M., Grossman L.S., Cavanaugh J.L., Davis J.M., Lewis D.A. Predicting the revolving door phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry 1995, 152:856-861.
19. Heeg B., Buskens E., Botteman M., Caleo S., Ingham M., Damen J., De Charro F., Van Hout B. The cost-effectiveness of atypicals in the UK. Value Health 2008, 11:1007-1021.
20. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., Weissert W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Mak. 2000, 20:332-342.
21. Hunt G.E., Siegfried N., Morley K., Sitharthan T., Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Schizophr. Bull. 2013, 40:18-20.
22. Insel T. Assessing the economic costs of serious mental illness. Am. J. Psychiatry 2008, 165:663-665.
23. Järbrink K., Kreif N., Benedict A., Locklear J. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr. Med. Res. Opin. 2009, 25:709-716.
24. Kay S.R., Flszbein A., Opfer L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261.
25. Kirby K.C., Amass L., McLellan A.T. Disseminating contingency management research to drug abuse treatment practitioners. Motivating Behavior Change Among Illicit-Drug Abusers: Research on Contingency Management Interventions 1999, 327-344. American Psychological Association, Washington, DC. S.T. Higgins, K.C. Silverman (Eds.).
26. Laudet A.B. The case for considering quality of life in addiction research and clinical practice. Addict. Sci. Clin. Pract. 2011, 6:44.
27. Lenert L.A., Rupnow M.F., Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual. Life Outcomes 2005, 3:57.
28. Lenert L.A., Sturley A.P., Rapaport M.H., Chavez S., Mohr P.E., Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr. Res. 2004, 71:155-165.
29. Lindenmayer J.-P., Bossie C.A., Kujawa M., Zhu Y., Canuso C.M. Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology 2007, 41:264-270.
30. Lindenmayer J.-P., Brown E., Baker R.W., Schuh L.M., Shao L., Tohen M., Ahmed S., Stauffer V.L. An excitement subscale of the positive and negative syndrome scale. Schizophr. Res. 2004, 68:331-337.
31. Lussier J.P., Heil S.H., Mongeon J.A., Badger G.J., Higgins S.T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006, 101:192-203.
32. Manning W.G., Mullahy J. Estimating log models: to transform or not to transform?. J. Health Econ. 2001, 20:461-494.
33. Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics 2010, 28:1109-1121.
34. McDonell M.G., Srebnik D., Angelo F., McPherson S., Lowe J.M., Sugar A., Short R.A., Roll J.M., Ries R.K. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am. J. Psychiatry 2013, 170:94-101.
35. McGovern M.P., Fox T.S., Xie H., Drake R.E. A survey of clinical practices and readiness to adopt evidence-based practices: dissemination research in an addiction treatment system. J. Subst. Abuse Treat. 2004, 26:305-312.
36. Milak M.S., Aniskin D.B., Eisenberg D.P., Prikhojan A., Cohen L.J., Yard S.S., Galynker I.I. The negative syndrome as a dimension: factor analyses of PANSS in major depressive disorder and organic brain disease compared with negative syndrome structures found in the schizophrenia literature. Cogn. Behav. Neurol. 2007, 20:113-120.
37. Mohr P.E., Cheng C.M., Claxton K., Conley R.R., Feldman J.J., Hargreaves W.A., Lehman A.F., Lenert L.A., Mahmoud R., Marder S.R. The heterogeneity of schizophrenia in disease states. Schizophr. Res. 2004, 71:83-95.
38. National Center for Health Statistics Health United States With Special Feature On Emergency Care, 2012 2013, National Center for Health Statistics Health United States, Hyattsville, MD.
39. Olmstead T.A., Petry N.M. The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine-or opioid-dependent outpatients. Drug Alcohol Depend. 2009, 102:108-115.
40. Olmstead T.A., Sindelar J.L., Easton C.J., Carroll K.M. The cost-effectiveness of four treatments for marijuana dependence. Addiction 2007, 102:1443-1453.
41. Olmstead T.A., Sindelar J.L., Petry N.M. Clinic variation in the cost-effectiveness of contingency management. Am. J. Addict. 2007, 16:457-460.
42. Olmstead T.A., Sindelar J.L., Petry N.M. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend. 2007, 87:175-182.
43. Park R.E. Estimation with heteroscedastic error terms. Econometrica 1966, 34:888.
44. Petry N.M., DePhilippis D., Rash C.J., Drapkin M., McKay J.R. Nationwide dissemination of contingency management: the Veterans Administration Initiative. Am. J. Addict. 2014, 23:205-210.
45. Petry N.M., Simcic F. Recent advances in the dissemination of contingency management techniques: clinical and research perspectives. J. Subst. Abuse Treat. 2002, 23:81-86.
46. Prendergast M., Podus D., Finney J., Greenwell L., Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006, 101:1546-1560.
47. Purnine D.M., Carey K.B., Maisto S.A., Carey M.P. Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders. J. Nerv. Ment. Dis. 2000, 188:653-661.
48. Rabinowitz J., Berardo C.G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. Res. 2013, 150:339-342.
49. RachBeisel J., Scott J., Dixon L. Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr. Serv. 1999, 50:1427-1434.
50. Rawson R.A., Huber A., McCann M., Shoptaw S., Farabee D., Reiber C., Ling W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch. Gen. Psychiatry 2002, 59:817-824.
51. Rawson R.A., McCann M.J., Flammino F., Shoptaw S., Miotto K., Reiber C., Ling W. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006, 101:267-274.
52. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
53. Roll J.M., Chermack S.T., Chudzynski J.E. Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: a feasibility study. Psychiatry Res. 2004, 125:61-64.
54. Seaman S.R., White I.R. Review of inverse probability weighting for dealing with missing data. Stat. Methods Med. Res. 2013, 22:278-295.
55. Sindelar J., Elbel B., Petry N.M. What do we get for our money? Cost-effectiveness of adding contingency management. Addiction 2007, 102:309-316.
56. Sindelar J.L., Olmstead T.A., Peirce J.M. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction 2007, 102:1463-1471.
57. Srebnik D., Sugar A., Coblentz P., McDonell M.G., Angelo F., Lowe J.M., Ries R.K., Roll J. Acceptability of contingency management among clinicians and clients within a co-occurring mental health and substance use treatment program. Am. J. Addict. 2013, 22:432-436.
58. Substance Abuse Mental Health Services Administration Report to Congress on the Prevention and Treatment of Co-Occurring Substance Abuse Disorders and Mental Disorders: Executive Summary 2002, SAMHSA, Rockville, MD.
59. Substance Abuse Mental Health Services Administration The ADSS Cost Study: Costs of Substance Abuse Treatment in the Specialty Sector 2003, DHHS, Rockville, MD.
60. Watkins K.E., Burnam A., Kung F.-Y., Paddock S. A national survey of care for persons with co-occurring mental and substance use disorders. Psychiatr. Serv. 2001, 52:1062-1068.
61. Watkins K.E., Burnam A.B., Kung F., Paddock S. A national survey of care for persons with co-occurring mental and substance use disorders. Psychiatr. Serv. 2001, 52:1062-1068.
62. Weiss R.D., Griffin M.L., Jaffee W.B., Bender R.E., Graff F.S., Gallop R.J., Fitzmaurice G.M. A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug Alcohol Depend. 2009, 104:212-219.